Bartle Doo Article Archives

Osiris Therapeutics Reports Fourth Quarter and Full Year 2012 Financial Results

COLUMBIA, Md.–(BUSINESS WIRE)– Osiris Therapeutics, Inc. (NAS: OSIR) the leading stem cell company focused on developing and marketing products to treat medical conditions in inflammatory, cardiovascular, orthopedic and wound healing markets, announced today its results for the fourth quarter and full year ended December 31, 2012.

Recent and Full Year Highlights

Achieved world’s first approval for a stem cell drug from Health Canada to market Prochymal® (remestemcel-L) for the treatment of acute graft versus host disease (GvHD) in children.
Established and deployed a direct sales force for Grafix®, a premium cellular repair matrix for serious wounds including diabetic foot ulcers, in 10 major metropolitan areas throughout the United States.
Launched Cartiform^TM, viable cartilage mesh for the treatment of articular cartilage injury.
Attained transitional pass-through status from the Center for Medicare & Medicaid Services (CMS) for Grafix, with Healthcare Common Procedure Coding System (HCPCS) C-Codes being designated and assignment of permanent HCPCS Q-codes.
Gross margin improved 12 percentage points to 70% with gross profit increasing to $2.1M for the quarter.
Reported product revenue of $7.8 million in 2012- representing a 520% increase over the prior year and 4Q12 revenue increasing 36% over 3Q12.
Reported year-end cash, receivables, and short-term investments of $37.2 million.

“With the approval of Prochymal, 2012 was an historic year for the entire field of stem cell medicine,” said C. Randal Mills, Ph.D., President and Chief Executive Officer of Osiris. “For Osiris, it was also a year of commercial transformation, having four products on the market and expanding capabilities in development, manufacturing, sales and marketing. Osiris is now a fully integrated commercial cell therapy company, well-positioned for future growth.”

Fourth Quarter Financial Results

Revenues during the fourth quarter of 2012 were $3.1 million, including Biosurgery product revenues of $2.9 million compared to $0.8 million over the same period of 2011. Gross margin during the fourth quarter was 70% compared to 58% …read more
Source: FULL ARTICLE at DailyFinance

Filed under: Investing

Sucampo Pharmaceuticals Announces Fourth Quarter and Full Year 2012 Financial Results and Operating Highlights Teleconference and Webcast

BETHESDA, Md.–(BUSINESS WIRE)– Sucampo Pharmaceuticals, Inc. (NAS: SCMP) , a global pharmaceutical company, today announced that it will host a webcast and teleconference with senior management to discuss its financial results and operating highlights for the fourth quarter and full year ended December 31, 2012, on Wednesday, March 13, 2012, at 5:00 pm Eastern. The press release announcing the financial results and operating highlights is expected to be released after the close of the capital markets that day.

Investors interested in accessing the live audio webcast of the teleconference may do so at http://investor.sucampo.com/phoenix.zhtml?c=201197&p=irol-calendar and should log on 10 to 15 minutes before the teleconference begins in order to download any software required. Presentation slides will be available via the webcast links. A replay of the webcast will also be available on the Company’s website for several days after the live event. Alternatively, investors may dial 800-688-0836 (domestic) or 617-614-4072 (international) and use passcode 62809438. A replay of the teleconference will be available by dialing 888-286-8010 (domestic) or 617-801-6888 passcode 95378400, approximately two hours after the teleconference concludes. The archive of the teleconference will remain available for 30 days.

About Sucampo Pharmaceuticals, Inc.

Sucampo Pharmaceuticals, Inc. is a global pharmaceutical company focused on innovative research, discovery, development and commercialization of proprietary drugs based on prostones. The therapeutic potential of prostones was first discovered by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo’s Chairman, Chief Executive Officer, Chief Scientific Officer, and co-founder. Prostones, naturally occurring fatty acid metabolites that have emerged as promising compounds with unique physiological activities, can be targeted for the treatment of unmet or underserved medical needs. For more information, please visit www.sucampo.com.

Sucampo Forward-Looking Statement

This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, future financial and operating results, and other statements that are not historical facts. The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the impact of …read more
Source: FULL ARTICLE at DailyFinance

Filed under: Investing

Staples, Inc. Announces Fourth Quarter and Full Year 2012 Performance

FRAMINGHAM, Mass.–(BUSINESS WIRE)– Staples, Inc. (NAS: SPLS) announced today the results for its fourth quarter and fiscal year ended February 2, 2013.

Filed under: Investing

Asset Acceptance Capital Corp. Reports Fourth Quarter and Full Year 2012 Results

Earnings per fully diluted share for the full year 2012 of $0.35; strong quarter of investment in purchased receivables

WARREN, Mich.–(BUSINESS WIRE)– Asset Acceptance Capital Corp. (NASDAQ: AACC), a leading purchaser and collector of charged-off consumer debt, today reported results for the quarter and fiscal year ended December 31, 2012.

In a separate press release, the Company also announced today that it had entered into an agreement in which Encore Capital Group, Inc. will acquire Asset Acceptance for $6.50 per share for a total equity value of approximately $200 million.

Fourth Quarter 2012 Financial Highlights

Cash collections for the fourth quarter of 2012 increased 4.3% compared to the same period of the prior year, to $85.7 million.

Fourth quarter revenues were $51.7 million, a decrease of 8.3% from the prior year period. The Company reported net impairments on purchased receivables of $0.9 million, which decreased revenues for the quarter, versus net impairment reversals of $2.6 million in the prior year period.

Rion Needs, President and CEO of Asset Acceptance Capital Corp, commented: “During the fourth quarter we continued to focus on our key initiatives, specifically, growing legal channel collections as well as identifying and implementing initiatives to improve our cost structure and productivity. Mr. Needs continued, “We continued to show progress in key performance metrics and have ambitious goals to further improve efficiency. While industry dynamics remained challenging, particularly the supply and pricing of charged-off receivables, we believe we remain well positioned to reach our operational and profitability goals in 2013 and beyond.”

Operating expenses were $46.8 million, an increase of $1.6 million compared to the prior year period. Results reflected a continued strategic investment in the Company’s legal channel and an increase in the related up-front costs ahead of associated collections. Legal investments increased to $9.4 million during the quarter compared to $7.2 million in the prior year period. Operating expenses also included restructuring charges in the fourth quarter of 2012 and 2011 of $0.4 million and $0.1 million, respectively. The restructuring charges were related to actions taken to close the Tempe, AZ and San Antonio, TX collection offices. Cost to collect for the quarter was 54.7%, an improvement of …read more
Source: FULL ARTICLE at DailyFinance

Filed under: Investing

Delek Logistics Partners, LP Reports Fourth Quarter and Full-Year 2012 Results

BRENTWOOD, Tenn.–(BUSINESS WIRE)– Delek Logistics Partners, LP (NYS: DKL) (“Delek Logistics“), a growth-oriented master limited partnership focused on owning and operating midstream energy infrastructure, today announced financial results for the fourth quarter and full year 2012.

Delek Logistics commenced operations on November 7, 2012 upon the successful completion of its initial public offering. For the 55 day period beginning November 7, 2012 and ended December 31, 2012 (the “post-closing period”), Delek Logistics reported net income of $8.4 million, or $0.34 per common partner unit.

For the post-closing period, distributable cash flow was $8.1 million and earnings before interest, taxes depreciation and amortization (“EBITDA“) was $10.2 million. Delek Logistics paid its first regular cash distribution of $5.5 million, or $0.224 per unit on February 14, 2013. This distribution was pro-rated for the post-closing period and corresponds to Delek Logistics‘ minimum quarterly distribution of $0.375 per unit, or $1.50 per unit on an annualized basis.

Uzi Yemin, Chairman and Chief Executive Officer of Delek Logistics‘ general partner, remarked: “The strong cash flow we generated since the initial public offering reflects a great start for us. Delek Logistics‘ EBITDA and distributable cash flow exceeded our expectations as our west Texas marketing business performed well and SALA Gathering System volumes were higher than expected. In addition, our cash flow was benefited by lower maintenance capital expenditures than forecast. Going forward, our focus will remain on delivering both growth and value as we explore opportunities to expand. We currently expect to recommend to the Board of Directors of Delek Logistics‘ general partner an increase in our quarterly distribution to $0.385 per unit for the quarter ending March 31, 2013, which would represent a 2.7 percent increase from our minimum quarterly distribution.”

Financial Results

Delek Logistics commenced operations on November 7, 2012 upon successful completion of its initial public offering (the “offering”) and the concurrent contribution of certain assets from its sponsor, Delek US Holdings, Inc. (NYS: DK) . For accounting purposes, the results of operations prior to November 7, 2012 from the assets and entities that were contributed to us concurrent with the offering, were attributed to Delek Logistics Partners, LP Predecessor (our “Predecessor”). Therefore, results from operations for the …read more
Source: FULL ARTICLE at DailyFinance

Filed under: Investing

Midstates Petroleum Reports Fourth Quarter and Full Year 2012 Financial and Operating Results

HOUSTON–(BUSINESS WIRE)– Midstates Petroleum Company, Inc. (NYS: MPO) (“Midstates” or the “Company”) announced today its financial and operating results for the three months and full year ended December 31, 2012. Midstates’ fourth quarter results were driven by a 91% sequential quarter increase in production, primarily resulting from the successful integration of the Eagle Energy Production, LLC (“Eagle”) property acquisition which closed October 1, 2012.

Highlights include:

Average daily production rose 91% to 15,592 net barrels of oil equivalent (“Boe”) per day from 8,182 net Boe per day in the third quarter of 2012; production from Mid-Continent operations (which includes Midstates’ Oklahoma and Kansas properties) averaged 7,207 Boe per day while production from Gulf Coast operations (which includes Midstates’ Louisiana properties) averaged 8,385 Boe per day.
Adjusted EBITDA totaled $48.6 million, up 49% from $32.7 million in the third quarter of 2012. See “Non-GAAP Financial Measures” in the tables below for a definition of Adjusted EBITDA and a reconciliation to net income (loss) and net cash provided by operating activities.
Adjusted Net Income (which excludes unrealized gains/losses on derivatives and transaction costs associated with the Eagle property acquisition and the related income tax effect) was $5.5 million compared with $1.7 million in the third quarter of 2012. See “Non-GAAP Financial Measures” in the tables below for a definition of Adjusted Net Income and a reconciliation to net income (loss).
Cash Operating Expenses (which includes lease operating and workover expenses, severance and ad valorem taxes, and the cash portion of general and administrative expenses, but excludes transaction costs associated with the Eagle property acquisition) were reduced 24% to $20.26 per Boe from $26.67 per Boe in the third quarter of 2012. See “Non-GAAP Financial Measures” in the tables below for a definition of Cash Operating Expenses and a reconciliation to Operating Expenses.
30 gross wells were spud during the fourth quarter of 2012 and 34 were placed into production. At quarter end, 12 were awaiting completion and seven were drilling. Since December 31, 2012, Midstates has spud 14 additional wells.
In the North …read more
Source: FULL ARTICLE at DailyFinance

Filed under: Investing

Pernix Therapeutics to Report Fourth Quarter and Full Year 2012 Financial Results on March 18, 2013

Management to Host a Conference Call on March 18 at 9:00 a.m. EST

THE WOODLANDS, Texas–(BUSINESS WIRE)– Pernix Therapeutics Holdings, Inc. (NAS: PTX) , a specialty pharmaceutical company, today announced that it will release its fourth quarter and full year 2012 financial results before the U.S. stock market opens on Monday, March 18, 2013 and has scheduled a conference call at 9:00 am EST that day to discuss the financial results.

The conference call will feature remarks by Cooper Collins, President and Chief Executive Officer, and David Becker, Chief Financial Officer. To participate in the conference call, please dial (888) 510-1786 (domestic) or (719) 785-1753 (international). Participants can reference the passcode 5442195. Please dial in approximately 5 minutes prior to the call.

The conference call will also be available via a live listen-only webcast and can be accessed through the Investor Relations section of the Company’s website, www.pernixtx.com. Please allow extra time prior to the call to visit the Company’s website and download any software that may be needed to listen to the webcast.

A replay of the conference call will be available through March 25, 2013, at (888) 203-1112 (domestic) or (719) 457-0820 (international). The passcode for the replay is 5442195. An online archive of the webcast will be available on the Company’s website for 30 days following the call.

About Pernix Therapeutics Holdings, Inc.

Pernix Therapeutics is a specialty pharmaceutical company primarily focused on the sales, marketing, manufacturing and development of branded, generic and OTC pharmaceutical products. The Company manages a portfolio of branded products, including the recently acquired Hawthorn Pharmaceuticals‘ product line. The Company’s branded products for the pediatrics market include CEDAX®, an antibiotic for middle ear infections, NATROBA™, a topical treatment for head lice marketed under an exclusive co-promotion agreement with ParaPRO, LLC, and a family of treatments for cough and cold (ZUTRIPRO®, BROVEX®, ALDEX® and PEDIATEX®). The Company’s branded products for gastroenterology include OMECLAMOX-PAK®, a 10-day treatment for H. pylori infection and duodenal …read more
Source: FULL ARTICLE at DailyFinance

Filed under: Investing

InSite Vision Reports Fourth Quarter and Full-Year 2012 Financial Results

ALAMEDA, Calif.–(BUSINESS WIRE)– InSite Vision Incorporated (OTCBB: INSV) today reported financial results for the quarter and year ended December 31, 2012. Revenues for the year ended December 31, 2012 were $21.6 million compared to $15.9 million for the same period in 2011. Net loss for the year ended December 31, 2012 was $8.3 million, or $0.06 per share, compared to a net loss of $6.9 million, or $0.06 per share, in 2011. Revenues for the fourth quarter of 2012 were $5.4 million compared to $3.1 million for the same period in 2011. Net loss for the fourth quarter of 2012 was $1.8 million, or $0.01 per share, compared to $3.2 million, or $0.02 per share, in the fourth quarter 2011. As of December 31, 2012, cash, cash equivalents and short-term investments totaled $9.3 million.

“InSite continues to advance its portfolio of innovative ophthalmic therapeutics for front-of-eye conditions. In 2012, we completed enrollment in two Phase 3 clinical studies – our DOUBle trial of AzaSite Plus and DexaSite for the treatment of blepharitis, and our Phase 3 clinical trial of BromSite for post-surgical pain and inflammation,” said Timothy Ruane, InSite’s Chief Executive Officer. “We look forward to announcing the results from these pivotal studies as we work with U.S. and EU regulatory agencies in 2013 to complete the necessary requirements for marketing approvals. In addition, we are actively building on our core competencies as we explore the potential for InSite’s DuraSite 2 platform to optimize the treatment of a number of ophthalmic conditions.”

Fourth Quarter Corporate and Commercial Highlights

In November 2012, InSite completed enrollment of more than 240 patients undergoing cataract surgery in its Phase 3 clinical trial of BromSite^™. The study is designed to evaluate the efficacy and safety of BromSite against the DuraSite^® vehicle alone in addressing post-surgical ocular inflammation and pain. BromSite combines a low dose (0.075%) of the non-steroidal anti-inflammatory drug (NSAID) bromfenac with InSite’s DuraSite drug delivery technology. Results from the Phase 3 clinical study are expected in the first quarter of 2013.
AzaSite^® royalties for the fourth quarter of 2012 were $4.8 million compared to $2.2 million for the same period of 2011. AzaSite is marketed in the U.S. by Merck for the treatment of bacterial conjunctivitis. Included in the AzaSite royalties for the fourth quarter of 2012 was a $2.6 million minimum royalty true-up …read more
Source: FULL ARTICLE at DailyFinance

Filed under: Investing

ImmunoCellular Therapeutics Announces Fourth Quarter and Full Year 2012 Financial Results

Conference Call Today at 5:00 pm ET

LOS ANGELES–(BUSINESS WIRE)– ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) today announced financial results for the year and quarter ended December 31, 2012.

For the year ended December 31, 2012, the Company incurred a net loss of $14.5 million, or $0.35 per basic and diluted share compared to a net loss of $5.7 million for the year ended December 31, 2011, or $0.21 per basic and diluted share. The net loss for 2012 includes a charge of $2.3 million related to the revaluation of the Company’s warrant derivatives and $496,000 in stock-based compensation. The net loss for 2011 included a credit of $2.9 million related to the revaluation of the warrant derivatives and charge of $1.2 million for stock-based compensation.

For the quarter ended December 31, 2012, the Company reported net income of $484,000, or $0.01 per basic and diluted share, compared to a net loss of $1,499,000, or $0.05 per basic and diluted share for the quarter ended December 31, 2011. The income for the quarter ended December 31, 2012, reflects a credit of $2.7 million related to the revaluation of the Company’s warrant derivatives. The net loss for the quarter ended December 31, 2011 reflects a credit of $1.4 million related to the revaluation of the Company’s warrant derivatives.

The Company reported that cash used in operations during 2012 was $12.4 million compared to $6.4 million in 2011. The increase reflects the continued ramp-up of the company’s Phase II clinical trial of ICT-107 as well as research and development activities for ICT-121 and ICT-140. Additionally, the Company’s general and administrative expenses increased in 2012 in order to develop and support its additional infrastructure. For the quarter ended December 31, 2012, the Company’s cash used in operations was $3.2 million compared to $1.8 million in the same period of 2011.

As of December 31, 2012, the Company had $26.2 million in cash. During 2012, the Company completed two equity financings which provided $28.6 million, net of expenses, and received $3.2 million from the exercise of warrants.

With respect to the estimates regarding the interim analysis of the ongoing ICT-107 phase II clinical trial, the completion and announcement of the interim analysis by the data monitoring …read more
Source: FULL ARTICLE at DailyFinance

Filed under: Investing

Sypris Solutions, Inc. to Announce Fourth Quarter and Full Year 2012 Financial Results, Host Conference Call and Webcast on March 12

LOUISVILLE, Ky.–(BUSINESS WIRE)– Sypris Solutions, Inc. (Nasdaq/NM:SYPR) will provide an online, real-time webcast and rebroadcast of its conference call for the fourth quarter and full year financial results for 2012 on Tuesday, March 12, 2013.

The live broadcast of Sypris Solutions‘ quarterly conference call will be available online at www.sypris.com or www.earnings.com on March 12, 2013, beginning at 9:00 a.m. (Eastern Time). The online replay will be available at approximately 11:00 a.m. (Eastern Time) and continue for 30 days. Related presentation materials will be posted to the “Investor Information” section of the Company’s web site at www.sypris.com, located under the sub-heading “Upcoming Events,” prior to the call. The presentation materials will be in Adobe Acrobat format. A copy of the Company’s press release announcing its earnings and any other financial and statistical information about the period to be presented in the conference call will also be available at the section of the Company’s web site entitled “Investor Information” at www.sypris.com.

Sypris Solutions is a diversified provider of technology-based outsourced services and specialty products. The Company performs a wide range of manufacturing and technical services, typically under multi-year, sole-source contracts with major corporations and government agencies in the markets for aerospace and defense electronics and truck components and assemblies. For more information about Sypris Solutions, visit its Web site at www.sypris.com.

Sypris Solutions, Inc.
Brian A. Lutes, 502-329-2000
Vice President & Chief Financial Officer

KEYWORDS: United States North America Kentucky

INDUSTRY KEYWORDS:

The article Sypris Solutions, Inc. to Announce Fourth Quarter and Full Year 2012 Financial Results, Host Conference Call and Webcast on March 12 originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

(function(c,a){window.mixpanel=a;var b,d,h,e;b=c.createElement(“script”);
b.type=”text/javascript”;b.async=!0;b.src=(“https:”===c.location.protocol?”https:”:”http:”)+
‘//cdn.mxpnl.com/libs/mixpanel-2.2.min.js’;d=c.getElementsByTagName(“script”)[0];
d.parentNode.insertBefore(b,d);a._i=[];a.init=function(b,c,f){function d(a,b){
var c=b.split(“.”);2==c.length&&(a=a[c[0]],b=c[1]);a[b]=function(){a.push([b].concat(
Array.prototype.slice.call(arguments,0)))}}var g=a;”undefined”!==typeof f?g=a[f]=[]:
f=”mixpanel”;g.people=g.people||[];h=[‘disable’,’track’,’track_pageview’,’track_links’,
…read more
Source: FULL ARTICLE at DailyFinance

Filed under: Investing

GameStop Corp. Announces Fourth Quarter and Full Year 2012 Earnings Release Date and Conference Call Webcast

GRAPEVINE, Texas–(BUSINESS WIRE)– GAMESTOP CORP. (NYS: GME) , today announced that the Company will report earnings results on Thursday, March 28, 2013 for its fourth quarter and full year ended Feb. 2, 2013.

The Company will host an investor conference call at 11:00 AM ET on the same day to review the company’s financial results and provide its 2013 outlook. This call can be accessed at GameStop Corp.’s investor relations home page at http://investor.gamestop.com. The call will be archived for two months on GameStop Corp.’s website.

ABOUT GAMESTOP CORP.

GameStop Corp. (NYSE:GME – News), a Fortune 500 and S&P 500 company headquartered in Grapevine, Texas, is the world’s largest multichannel video game retailer. GameStop’s retail network and family of brands include 6,650 company-operated stores in 15 countries worldwide and online at www.GameStop.com. The network also includes: www.Kongregate.com, a leading browser-based game site; Game Informer® magazine, the leading print & digital video game publication; Spawn Labs, a streaming technology company; and a digital PC game distribution platform available at www.GameStop.com/PCGames.

General information on GameStop Corp. can be obtained at the company’s corporate website. Follow GameStop on Twitter @ www.twitter.com/GameStop and find GameStop on Facebook @ www.facebook.com/GameStop.

GameStop Corp.
Matt Hodges, 817-424-2130
Vice President of Public and Investor Relations

KEYWORDS: United States North America Texas

INDUSTRY KEYWORDS:

The article GameStop Corp. Announces Fourth Quarter and Full Year 2012 Earnings Release Date and Conference Call Webcast originally appeared on Fool.com.

Filed under: Investing

ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2012 Financial Results on March 12, 2013

ACADIA to Host Conference Call and Webcast on Tuesday, March 12, 2013, at 5:00 p.m. Eastern Time

SAN DIEGO–(BUSINESS WIRE)– ACADIA Pharmaceuticals Inc. (NAS: ACAD) , a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will report its financial results for the fourth quarter and year ended December 31, 2012 on Tuesday, March 12, 2013, after the U.S. financial markets close. ACADIA‘s management will host a conference call and webcast on Tuesday, March 12, 2013, at 5:00 p.m. Eastern Time to discuss ACADIA‘s financial results and development programs.

The conference call may be accessed by dialing 866-510-0712 for participants in the U.S. or Canada and 617-597-5380 for international callers (reference passcode 78191729). A telephone replay of the conference call may be accessed through March 26, 2013 by dialing 888-286-8010 for callers in the U.S. or Canada and 617-801-6888 for international callers (reference passcode 59394169). The conference call also will be webcast live on ACADIA‘s website, www.acadia-pharm.com, under the investors section and will be archived there until March 26, 2013.

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders. ACADIA has a pipeline of product candidates led by pimavanserin, which is in Phase III development as a potential first-in-class treatment for Parkinson’s disease psychosis. ACADIA also has clinical-stage programs for chronic pain and glaucoma in collaboration with Allergan, Inc. and two advanced preclinical programs directed at Parkinson’s disease and other neurological disorders. All product candidates are small molecules that emanate from discoveries made at ACADIA. ACADIA maintains a website at www.acadia-pharm.com to which ACADIA regularly posts copies of its press releases as well as additional information and through which interested parties can subscribe to receive email alerts.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include but are not limited to statements related …read more
Source: FULL ARTICLE at DailyFinance

Filed under: Investing

Checkpoint Systems, Inc. Announces Fourth Quarter and Full-Year 2012 Results

2012 Net Revenues and Free Cash Flow Exceed Guidance

2012 Adjusted non-GAAP Operating Margin at the High End of Guidance

Company Provides 2013 Guidance, In-Line with Previous Outlook

Results Reflect Decision to Sell U.S. and Canadian CheckView ^® Business

THOROFARE, N.J.–(BUSINESS WIRE)– Checkpoint Systems, Inc. (NYSE: CKP) today reported financial results for the fourth quarter and full-year ended December 30, 2012. These results report the U.S. and Canadian CheckView^® business as discontinued operations, reflecting the Company’s decision to sell the business.

Fourth Quarter GAAP Results – Continuing Operations:

Net revenues from continuing operations in the fourth quarter of 2012 decreased 11.1%, 9.5% on a constant currency basis, to $200.2 million from $225.1 million in the fourth quarter of 2011. Gross profit margins were 39.3% compared with 41.1% in the 2011 fourth quarter. SG&A expenses of $61.4 million decreased by $9.7 million, or 13.6% compared with the same period last year, driven by $7.1 million of incremental savings from the global restructuring programs, as well as continued tight expense control.

The operating loss of $19.7 million decreased $28.0 million from the same period last year, even though the 2012 loss included a non-cash $38.3 million goodwill impairment in Retail Merchandising Solutions as well as restructuring, litigation settlement and acquisition expenses. These were partially offset by an insurance settlement received against fraudulent activities in Checkpoint’s Canadian operations discovered in 2011, a gain on the sale of our non-strategic Suzhou, China subsidiary, and tax valuation allowance adjustments.

Net loss from continuing operations was $0.76 per diluted share compared with a loss of $0.35 per diluted share in the same period last year. In addition to the items noted above, the loss from continuing operations was impacted in both 2012 and 2011 by a valuation allowance on U.S. deferred tax assets recorded in 2011 that creates higher than normal volatility in income tax expense, depending on the mix of pre-tax income and losses in the countries …read more
Source: FULL ARTICLE at DailyFinance

Filed under: Investing

Constellation Energy Partners Reports Fourth Quarter and Full Year 2012 Results; Alabama Asset Sale Results in Lower Debt

CEP’s Adjusted EBITDA improves by 18% in the fourth quarter 2012
CEP’s Mid-Continent drilling efforts result in net oil production of 396 barrels per day in the fourth quarter 2012, an increase of 45% over the prior quarter
CEP reports a 14% increase in oil production year-on-year
CEP’s strategic focus to remain on Mid-Continent oil opportunities, with oil production expected to account for 50% of CEP’s 2013 sales revenue

HOUSTON–(BUSINESS WIRE)– Constellation Energy Partners LLC (NYSE MKT: CEP) today reported fourth quarter and full year 2012 results.

The company produced 3,119 MMcfe during the fourth quarter, for average daily net production of 33.9 MMcfe for the quarter and 34.5 MMcfe for the full year 2012. Net oil production for the fourth quarter was 396 barrels per day, which represents an increase of approximately 45% compared to the third quarter of 2012. For the full year 2012, net oil production averaged 329 barrels per day, an increase of approximately 14% compared to the full year 2011. During 2012, approximately 94% of the company’s production was natural gas and 6% of the company’s production was oil.

Revenue totaled $17.3 million for the fourth quarter 2012 and $59.3 million for the full year 2012. Included in total revenue for the full year 2012 is revenue from sales of $40.5 million, of which approximately 71% was from natural gas sales and 29% was from oil sales. During 2011, approximately 82% of the company’s sales revenue was from natural gas sales and 18% was from oil sales. The balance of the company’s full year 2012 total revenue came from hedge settlements ($24.4 million), services provided to third parties ($3.2 million), and losses on mark-to-market activities ($8.7 million), which is a non-cash item.

Operating costs, which include lease operating expenses, production taxes and general …read more
Source: FULL ARTICLE at DailyFinance

Filed under: Investing

Lakes Entertainment to Host Conference Call and Webcast on Results for Fourth Quarter and Full Year 2012

MINNEAPOLIS–(BUSINESS WIRE)– Lakes Entertainment, Inc. (NAS: LACO) announced it will host a conference call and webcast to discuss the Company’s fourth quarter and full year 2012 financial results on Tuesday, March 12, 2013, at 1:00 p.m. Central Time (2:00 p.m. Eastern). The Company will issue financial results prior to the call.

Chairman of the Board and Chief Executive Officer Lyle Berman, and President and Chief Financial Officer Tim Cope, will recap the fourth quarter and full year 2012 results and provide a business update.

WHEN:

Tuesday, March 12, 2013
Conference Call: 1:00 p.m. Central Time (2:00 p.m. Eastern Time)
Dial-in Number: 866-510-0705
Passcode: 38719896
WEBCAST: To listen to a live webcast of the conference call, go to Lakes’ web site, www.lakesentertainment.com, and click on “Conference Call.”

The webcast replay will be available from 3:00 p.m. Central Time, March 12, 2013, until March 26, 2013, on the Lakes Entertainment website at www.lakesentertainment.com. Listening to the webcast requires speakers and Windows Media Player. If you do not have Media Player, download the free software at www.windowsmedia.com.

If you do not have Internet access and want to listen to an audio replay, call 888-286-8010 and enter conference call code 15236172. The audio replay will be available beginning at 3:00 p.m. Central Time, March 12, 2013, until 12:00 p.m. Central Time, March 26, 2013.

About Lakes Entertainment

Lakes Entertainment, Inc. currently owns the Rocky Gap Lodge & Golf Resort near Cumberland, Maryland. Lakes has a management agreement with the Shingle Springs Band of Miwok Indians to manage the Red Hawk Casino. Lakes has an investment in Rock Ohio Ventures, LLC casino developments in Ohio.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by Lakes Entertainment, Inc.) contains statements that are forward-looking, such as statements relating to plans for future expansion and other business development activities as well as other capital spending, financing sources and the effects of regulation (including gaming and tax regulation) and competition. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future and, accordingly, such results may differ from those expressed in any …read more
Source: FULL ARTICLE at DailyFinance

March 4, 2013 Bartle Doo Leave a comment

Filed under: Investing

Navidea Biopharmaceuticals to Announce Fourth-Quarter and Full-Year 2012 Financial Results on Wednesday, March 6, 2013

– Conference call with investment community on Thursday, March 7, 2013 –

DUBLIN, Ohio–(BUSINESS WIRE)– Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that the Company will report its financial results for the fourth quarter and full year 2012 on Wednesday, March 6, 2013 after market close. The announcement will be followed by a conference call with the investment community, on Thursday, March 7, 2013, at 8:30 a.m. EST to provide a business update and discuss its financial and operational results.

Investors and the public are invited to listen live to the call. If you are unable to join the live call, an archived version will be available until March 21, 2013. The conference call can be accessed as follows:



CONFERENCE CALL INFORMATION
TO PARTICIPATE LIVE:						TO LISTEN TO A REPLAY:

March 4, 2013 Bartle Doo Leave a comment

Filed under: Investing

FXCM Inc. Announces Fourth Quarter and Full-Year 2012 Earnings Conference Call

NEW YORK–(BUSINESS WIRE)– FXCM Inc., (NYS: FXCM) an online provider of forex trading and related services worldwide, announced that it will report its 2012 fourth quarter and full year financial results before the opening of the U.S. financial markets on Thursday, March 7, 2013.

The Company will host a conference call to discuss the results at 8:15 a.m. (EST). This conference call will be available to domestic participants by dialing 877.303.9132 and 408.337.0136 for international participants. The conference ID number is 17412832.

A live, audio webcast, a copy of FXCM‘s earnings release, and presentation slides for this conference call will be available at http://ir.fxcm.com/.

Additionally, FXCM will release its monthly business metrics for February 2013 in the earnings press release on Thursday, March 7, 2013.

An audio replay of this conference call will be made available shortly after the call by dialing 855.859.2056 in the U.S. or 404.537.3406 from abroad, and entering passcode 17412832.

About FXCM Inc.

FXCM Inc. is a global online provider of foreign exchange (forex) trading and related services to retail and institutional customers worldwide.

At the heart of FXCM‘s client offering is No Dealing Desk forex trading. Clients benefit from FXCM‘s large network of forex liquidity providers enabling FXCM to offer competitive spreads on major currency pairs. Clients have the advantage of mobile trading, one-click order execution, and trading from real-time charts. FXCM‘s UK subsidiary, Forex Capital Markets Limited, also offers CFD products with no re-quote trading and allows clients to trade forex, oil, gold, silver, and stock indices on one platform. In addition, FXCM offers educational courses on forex trading and provides free news and market research through DailyFX.com.

Trading foreign exchange and CFDs on margin carries a high level of risk and may not be suitable for all. Read full disclaimer.

All references to “FXCM” refer to FXCM Inc. and its consolidated subsidiaries.

FXCM Inc.
Jaclyn Klein, 646-432-2463
Vice President, Corporate Communications and Investor Relations
…read more
Source: FULL ARTICLE at DailyFinance

March 4, 2013 Bartle Doo Leave a comment